LifeStance Health Group (NASDAQ:LFST) Upgraded at Wall Street Zen

LifeStance Health Group (NASDAQ:LFST) was upgraded by Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Saturday.

Several other research firms have also weighed in on LFST. Zacks Research raised shares of LifeStance Health Group from a “hold” rating to a “strong-buy” rating in a report on Monday, April 27th. Barclays lifted their price target on shares of LifeStance Health Group from $8.00 to $9.00 and gave the company an “overweight” rating in a report on Friday, March 6th. JPMorgan Chase & Co. boosted their price target on shares of LifeStance Health Group from $8.00 to $9.00 and gave the company a “neutral” rating in a research report on Thursday, May 14th. Jefferies Financial Group raised shares of LifeStance Health Group to a “strong-buy” rating in a research note on Thursday, March 12th. Finally, BTIG Research lifted their target price on shares of LifeStance Health Group from $11.00 to $12.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, LifeStance Health Group currently has an average rating of “Moderate Buy” and a consensus target price of $9.75.

LifeStance Health Group Price Performance

Shares of LFST stock opened at $11.27 on Friday. The stock’s fifty day simple moving average is $8.32 and its 200 day simple moving average is $7.40. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.48 and a quick ratio of 1.48. The firm has a market cap of $4.37 billion, a price-to-earnings ratio of 187.83 and a beta of 1.12. LifeStance Health Group has a one year low of $3.74 and a one year high of $11.62.

LifeStance Health Group (NASDAQ:LFST) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.04 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.03. LifeStance Health Group had a return on equity of 1.56% and a net margin of 1.55%.The firm had revenue of $403.48 million for the quarter, compared to analysts’ expectations of $387.46 million. LifeStance Health Group’s revenue for the quarter was up 21.2% compared to the same quarter last year. On average, analysts expect that LifeStance Health Group will post 0.12 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Robert Bessler sold 894,337 shares of the firm’s stock in a transaction on Friday, June 26th. The stock was sold at an average price of $10.13, for a total value of $9,059,633.81. Following the completion of the sale, the director directly owned 539,763 shares in the company, valued at approximately $5,467,799.19. This trade represents a 62.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Darren M. Black sold 5,899,661 shares of LifeStance Health Group stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $8.02, for a total value of $47,315,281.22. Following the completion of the transaction, the director directly owned 23,310,115 shares of the company’s stock, valued at $186,947,122.30. This represents a 20.20% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 7,762,394 shares of company stock worth $64,107,859. 3.20% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On LifeStance Health Group

A number of institutional investors have recently modified their holdings of LFST. Larson Financial Group LLC lifted its position in shares of LifeStance Health Group by 19,952.6% during the fourth quarter. Larson Financial Group LLC now owns 3,810 shares of the company’s stock worth $27,000 after purchasing an additional 3,791 shares in the last quarter. KBC Group NV acquired a new stake in shares of LifeStance Health Group in the first quarter valued at approximately $29,000. EverSource Wealth Advisors LLC increased its holdings in shares of LifeStance Health Group by 359.1% in the first quarter. EverSource Wealth Advisors LLC now owns 6,909 shares of the company’s stock valued at $44,000 after purchasing an additional 5,404 shares in the last quarter. PNC Financial Services Group Inc. raised its position in LifeStance Health Group by 615.3% in the 1st quarter. PNC Financial Services Group Inc. now owns 9,285 shares of the company’s stock worth $59,000 after purchasing an additional 7,987 shares during the last quarter. Finally, Assetmark Inc. raised its position in LifeStance Health Group by 17.0% in the 1st quarter. Assetmark Inc. now owns 9,419 shares of the company’s stock worth $60,000 after purchasing an additional 1,367 shares during the last quarter. 85.50% of the stock is owned by institutional investors.

LifeStance Health Group Company Profile

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.